XML 70 R58.htm IDEA: XBRL DOCUMENT
v3.25.1

Commitments and Contingencies (Details) $ in Thousands |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 16, 2025 | Apr. 07, 2025 USD ($) | Aug. 27, 2024 | Jul. 03, 2024 litigationCase | Dec. 15, 2023 litigationCase | Feb. 24, 2023 | Feb. 15, 2023 litigationCase | Jan. 03, 2023 | Jul. 21, 2022 | Jun. 22, 2022 litigationCase | Jun. 23, 2020 litigationCase | Mar. 31, 2023 patent | Feb. 28, 2023 patent | Jul. 31, 2021 patent | Jun. 30, 2021 patent | Mar. 31, 2025 USD ($) | Dec. 31, 2024 USD ($) | Jun. 07, 2022 patent | May 13, 2021 patent
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued litigation settlement expenses | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 172,000 | $ 0 |  |
Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Settlement amount | $ |  | $ 145,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Teamsters and GEHA Lawsuits |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | litigationCase |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |
Avadel Pharmaceuticals plc Lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Infringed patents suit, number of patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5
Infringed patents suit, other party counterclaim, number of patents requested to be delisted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1
Number of days provided to delist patent (in days) |  |  |  |  |  | 14 days |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents, paragraph IV certification notice filed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
Royalty rate for future sale (as a percent) |  |  | 3.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of days requested for FDA to take action (in days) |  |  |  |  |  |  |  |  | 14 days |  |  |  |  |  |  |  |  |  |
Lupin Lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | litigationCase |  |  |  |  |  |  | 2 |  |  | 2 |  |  |  |  |  |  |  |  |
Infringed patents suit, number of patents |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 |  |  |  |  |
Number of patents, paragraph IV certification notice filed |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 |  |  |  |
FDA stay of approval period (in months) |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 months |  |  |  |  |
Lupin Lawsuit | Xywav |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FDA recognition of orphan drug exclusivity, period (in years) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 years |  |  |  |
Teva Lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Infringed patents suit, number of patents |  |  |  |  |  |  |  |  |  |  |  | 13 |  |  |  |  |  |  |
FDA stay of approval period (in months) |  |  |  |  |  |  |  |  |  |  |  | 30 months |  |  |  |  |  |  |
Infringed patents suit, number of patents |  |  |  |  |  |  |  |  |  |  |  |  | 13 |  |  |  |  |  |
Epidiolex Patent Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | litigationCase |  |  |  | 6 | 7 |  |  |  |  |  |  |  |  |  |  |  |  |  |
FDA stay of approval period (in months) |  |  |  |  |  |  |  | 30 months |  |  |  |  |  |  |  |  |  |  |
Defitelio Patent Litigation | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FDA stay of approval period (in months) | 30 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition FDA Recognition Of Orphan Drug Exclusivity, Period + References No definition available. + Details
Name: | jazz_FDARecognitionOfOrphanDrugExclusivityPeriod
Namespace Prefix: | jazz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition FDA Stay Of Approval Period + References No definition available. + Details
Name: | jazz_FDAStayOfApprovalPeriod
Namespace Prefix: | jazz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Infringed Patents Suit, Number Of Patents + References No definition available. + Details
Name: | jazz_InfringedPatentsSuitNumberOfPatents
Namespace Prefix: | jazz_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Infringed Patents Suit, Other Party Counterclaim, Number Of Patents Requested To Be Delisted + References No definition available. + Details
Name: | jazz_InfringedPatentsSuitOtherPartyCounterclaimNumberOfPatentsRequestedToBeDelisted
Namespace Prefix: | jazz_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Days Provided To Delist Patent + References No definition available. + Details
Name: | jazz_NumberOfDaysProvidedToDelistPatent
Namespace Prefix: | jazz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Patents, Paragraph IV Certification Notice Filed + References No definition available. + Details
Name: | jazz_NumberOfPatentsParagraphIVCertificationNoticeFiled
Namespace Prefix: | jazz_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Plaintiff, Number Of Days Requested For FDA To Take Action + References No definition available. + Details
Name: | jazz_PlaintiffNumberOfDaysRequestedForFDAToTakeAction
Namespace Prefix: | jazz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Rate For Future Sale, Percentage + References No definition available. + Details
Name: | jazz_RoyaltyRateForFutureSalePercentage
Namespace Prefix: | jazz_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_LitigationReserveCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jazz_TeamstersAndGEHALawsuitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jazz_AvadelPharmaceuticalsPlcLawsuitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jazz_LupinLawsuitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jazz_XywavMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jazz_TevaLawsuitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jazz_EpidiolexPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=jazz_DefitelioPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |